Bucillamine

布西拉明

Report date: 2026/03/17 15:13:40
NME

Base Information

Drug NameBucillamine
Drug Alias Name布溪那明bucillaminumbucillaminebucilaminaRimatil +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)CystinuriaGout +[4] 
Global Approved IndicationsArthritis, Rheumatoid
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date1987/09/01
Country/TerritoryUnited StatesPuerto RicoJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesRevive Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDefence Research And Development CanadaAYUMI Pharmaceutical Corp
Inactive CompaniesRevive Therapeutics Ltd
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)CystinuriaGout

Other Information

ATC CodeM01CC02
Related LinksWikipediaDrugBankKEGG